{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BI10773",
    "query": {
      "intervention": "BI10773"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 142,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BI10773&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T10:10:11.481Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05081219",
      "title": "SNIFF - Combo INI+EMPA Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Cognitive Impairment",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Insulin (Humulin® R U-100)",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Aptar Pharma CPS Intranasal Delivery Device",
          "type": "DEVICE"
        },
        {
          "name": "Placebo (Insulin Diluent)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Capsules)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 47,
      "start_date": "2021-09-14",
      "completion_date": "2024-09-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05081219"
    },
    {
      "nct_id": "NCT05465317",
      "title": "Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidate-4 inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62197,
      "start_date": "2022-08-08",
      "completion_date": "2023-05-02",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05465317"
    },
    {
      "nct_id": "NCT06926660",
      "title": "A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Vicadrostat",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching vicadrostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 492,
      "start_date": "2025-07-18",
      "completion_date": "2026-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 37,
      "location_summary": "Huntsville, Alabama • Anaheim, California • San Dimas, California + 33 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Valencia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06926660"
    },
    {
      "nct_id": "NCT03627039",
      "title": "Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "SGLT2",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2018-09-01",
      "completion_date": "2020-08-01",
      "has_results": false,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03627039"
    },
    {
      "nct_id": "NCT04203927",
      "title": "Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type2 Diabetes",
        "Insulin Sensitivity"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-02-01",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2022-02-10",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04203927"
    },
    {
      "nct_id": "NCT06828731",
      "title": "Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prediabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 10mg daily",
          "type": "DRUG"
        },
        {
          "name": "Lifestyle education",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Charles George VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "35 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-06",
      "completion_date": "2025-09-05",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 1,
      "location_summary": "Asheville, North Carolina",
      "locations": [
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06828731"
    },
    {
      "nct_id": "NCT03173963",
      "title": "Empaglifozin in Early Diabetic Kidney Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Kidney Disease",
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-05-27",
      "completion_date": "2020-02-21",
      "has_results": false,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173963"
    },
    {
      "nct_id": "NCT07547878",
      "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Finerenone",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Lotensin",
          "type": "DRUG"
        },
        {
          "name": "Capoten",
          "type": "DRUG"
        },
        {
          "name": "Enalapril",
          "type": "DRUG"
        },
        {
          "name": "Monopril",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Univasc",
          "type": "DRUG"
        },
        {
          "name": "Aceon",
          "type": "DRUG"
        },
        {
          "name": "Accupril",
          "type": "DRUG"
        },
        {
          "name": "Altace",
          "type": "DRUG"
        },
        {
          "name": "Mavik",
          "type": "DRUG"
        },
        {
          "name": "Edarbi",
          "type": "DRUG"
        },
        {
          "name": "Atacand",
          "type": "DRUG"
        },
        {
          "name": "Avapro",
          "type": "DRUG"
        },
        {
          "name": "Cozaar",
          "type": "DRUG"
        },
        {
          "name": "Benicar",
          "type": "DRUG"
        },
        {
          "name": "Micardis",
          "type": "DRUG"
        },
        {
          "name": "Diovan",
          "type": "DRUG"
        },
        {
          "name": "Invokana",
          "type": "DRUG"
        },
        {
          "name": "Farxiga",
          "type": "DRUG"
        },
        {
          "name": "Jardiance",
          "type": "DRUG"
        },
        {
          "name": "Ertugliflozin",
          "type": "DRUG"
        },
        {
          "name": "Brenzavvy",
          "type": "DRUG"
        },
        {
          "name": "Sotagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-04-30",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 1,
      "location_summary": "Temple, Texas",
      "locations": [
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07547878"
    },
    {
      "nct_id": "NCT03448419",
      "title": "This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 312,
      "start_date": "2018-03-20",
      "completion_date": "2019-10-07",
      "has_results": true,
      "last_update_posted_date": "2020-11-27",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 41,
      "location_summary": "Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03448419"
    },
    {
      "nct_id": "NCT07064473",
      "title": "EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Hypertension",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Vicadrostat",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Vicadrostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11800,
      "start_date": "2025-07-22",
      "completion_date": "2029-12-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-09T10:10:11.481Z",
      "location_count": 210,
      "location_summary": "Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 173 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07064473"
    }
  ]
}